Truist Financial Cuts Genmab A/S (NASDAQ:GMAB) Price Target to $45.00

Genmab A/S (NASDAQ:GMAB - Get Free Report) had its price target dropped by equities researchers at Truist Financial from $50.00 to $45.00 in a report released on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Truist Financial's price objective would indicate a potential upside of 123.51% from the company's previous close.

A number of other analysts have also commented on GMAB. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research report on Thursday, February 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Genmab A/S has an average rating of "Moderate Buy" and a consensus price target of $41.33.

Genmab A/S Trading Down 8.4 %

NASDAQ GMAB traded down $1.85 during trading hours on Tuesday, hitting $20.13. 1,480,995 shares of the company's stock were exchanged, compared to its average volume of 885,455. The firm has a market cap of $13.32 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 2.65 and a beta of 0.98. The stock has a 50-day simple moving average of $21.30 and a 200 day simple moving average of $22.59. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.88.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Employees Retirement System of Texas bought a new position in shares of Genmab A/S in the fourth quarter valued at approximately $1,648,000. Mackenzie Financial Corp bought a new position in Genmab A/S in the 4th quarter valued at $689,000. GTS Securities LLC purchased a new stake in shares of Genmab A/S during the 4th quarter valued at $1,552,000. Vise Technologies Inc. raised its stake in shares of Genmab A/S by 41.7% during the 4th quarter. Vise Technologies Inc. now owns 12,892 shares of the company's stock worth $269,000 after purchasing an additional 3,794 shares during the period. Finally, Voloridge Investment Management LLC grew its position in Genmab A/S by 102.4% during the fourth quarter. Voloridge Investment Management LLC now owns 1,110,191 shares of the company's stock valued at $23,170,000 after buying an additional 561,767 shares during the period. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.